ArticleCurrent oncology (Toronto, Ont.)2025
Exploring Cancer Patients' and Caregivers' Perspectives and Knowledge Regarding Biomarker Testing in Canada.
Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While biomarker testing can provide various benefits for cancer patient outcomes, numerous challenges persist that cause inequities in access across Canada. An online survey consisting of 51 questions was disseminated to evaluate biomarker testing and precision medicine knowledge and experiences from Canadian patients and caregivers. Responses were recorded between June 2023 and January 2024 and assessed various aspects of the biomarker testing experience including the expectations and challenges of patients. Quantitative and qualitative analyses were conducted using Microsoft Excel and R for descriptive and correlative data analysis, respectively. Among the 74 responses, patients reported an overall moderate experience with positive outcomes for those who underwent biomarker testing, including changes to treatment plans and the shrinking of tumours. The main challenges identified included knowledge gaps, a lack of testing availability, turnaround time for results, and financial constraints, all of which contribute to the disparities in biomarker testing access. Qualitative analysis of responses further emphasized a strong patient desire for patient-centred care and collaborative decision-making for biomarker testing options and treatment planning. Addressing these challenges through increased education, policy advocacy, and advancing infrastructure can help to reduce interprovincial inequities in biomarker testing and contribute to improving cancer patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.